Seeking Alpha
 

Boston Scientific Corporation (BSX)

- NYSE
  • Mon, Mar. 2, 7:38 AM
    • Boston Scientific (NYSE:BSX) acquires American Medical Systems' urology product product line for $1.6B in up-front cash plus a potential milestone of $50M. The assets will become part of Boston Sci's Urology and Women's Health unit.
    • The deal includes the minimally invasive GreenLight XPS and HPS Laser Therapy Systems for treating benign prostate hyperplasia (enlarged prostate), the AMS 800 Urinary Control System for treating stress urinary incontinence and the AMS 700 Inflatable Penile Prosthesis for treating erectile dysfunction.
    • The 800-employee AMS business generated ~$400M in sales last year with non-GAAP operating income of ~$130M (GAAP operating income was ~$60M). The acquisition is expected to deliver pre-tax synergies of more than $50M by the end of 2018. On a non-GAAP basis, the deal will be neutral to earnings per share this year, accretive by $0.03 in 2016, ~$0.07 in 2017 and increasingly accretive thereafter.
    • The transaction is expected to close in Q3.
    | Comment!
  • May. 15, 2014, 7:41 AM
    • Boston Scientific (BSX) has agreed to acquire Bayer's (BAYRY) Interventional device business for $415M.
    • The deal that will strengthen Boston's portfolio of products for treating peripheral vascular disease, with the company to receive systems used in cardiology, radiology and peripheral vascular procedures.
    • The unit generated $120M in sales last year. (PR)
    | 1 Comment
  • May. 6, 2014, 6:15 PM
    • Owning a minority interest of 28% apparently wasn't enough for Boston Scientific (BSX -0.9%) because it bought the rest of pre-commercial stage IoGyn today for $65M.
    • IoGyn's flagship product, the Symphion System, is a hysteroscopic device used to remove intrauterine tissue like fibroids and polyps. It complements BSX's Genesys HTA System for abnormal uterine bleeding.
    • The Symphion resects the uterine growth and then removes the tissue through its recirculating and filtering fluid management system via suction. This avoids the potential to spread rare cases of sarcoma which is a potential risk with morcellation systems.
    | Comment!
  • Jun. 28, 2013, 11:29 AM
    C.R. Bard (BCR +1%) say sold certain assets of its Electrophysiology division to Boston Scientific (BSX +1.6%) for $275M in cash. BCR's Electrophysiology division manufactures and markets medical equipment, catheters and accessories used in cardiac electrophysiology procedures. Annual net sales linked to the divested assets totaled aoound $111M in 2012. The company expects the sale to be about $0.05 dilutive to 2013 EPS and immaterial to 2014 guidance previously provided.
    | Comment!
  • Jan. 31, 2013, 4:09 PM
    Despite the marketshare gains Cardiovascular Systems (CSII) has made with its Diamondback and Stealth devices for treating narrowed or blocked arteries in the leg, the real value in the company may lie in its takeout potential, says Seeking Alpha contributor Stephen Simpson. CR Bard, Cook, BSX, JNJ, MDT and ABT all have sales forces in the peripheral treatment space, making them solid candidates for a possible buyout of CSII.
    | Comment!
  • Nov. 8, 2012, 8:01 AM
    Boston Scientific (BSX) agrees to acquire privately held Vessix Vascular for $125M up front and milestone payments of up to $300M in 2013-2017. Vessix develops the Vascular V2 Renal Denervation System for the treatment of hypertension, which BSX expects will "be a multi-billion dollar market by 2020."
    | 1 Comment
  • Oct. 8, 2012, 5:03 PM
    Boston Scientific (BSX) agrees to acquire privately-held Rhythmia Medical, a developer of mapping and navigation solutions for use in cardiac catheter ablations and other electrophysiology procedures. The deal includes a $90M upfront payment plus as much as $175M in milestone-based payments. BSX -1.2% AH.
    | Comment!
  • Sep. 19, 2012, 9:49 AM
    Boston Scientific (BSX) agrees to acquire privately held BridgePoint Medical, which develops a catheter-based system to treat highly diseased coronary arteries as a means of restoring blood flow to the heart. Financial terms weren't disclosed. (PR)
    | Comment!
  • Mar. 9, 2012, 4:50 AM
    Boston Scientific (BSX) announced yesterday it would buy privately-held Cameron Health for $150M in cash and up to $1.2B in additional payments if the company's new kind of defibrillator achieves certain regulatory and sales milestones. The deal will have a 1 cent negative impact on on BoSci's 2012 adjusted earnings.
    | Comment!
Visit Seeking Alpha's
BSX vs. ETF Alternatives
Company Description
Boston Scientific Inc is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.